Results 1 to 10 of about 218,733 (151)
Cabergoline Treatment in Invasive Giant Prolactinoma [PDF]
Clinical Medicine Insights: Case Reports, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Mussa H Almalki
exaly +7 more sources
Surgical Management of Giant Prolactinomas: A Descriptive Study
International Journal of Endocrinology, 2023 Introduction. Giant prolactinoma (GP) is a rare pituitary lactotropic cell tumor larger than 4 cm in its widest dimension, and is less likely than a smaller prolactinoma to achieve prolactin normalization on dopamine agonist (DA) monotherapy.
Michelle D. Lundholm +5 more
doaj +4 more sources
A Case of Giant Prolactinoma, Initially Misdiagnosed as Sinonasal Neuroendocrine Carcinoma
Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2015 Giant prolactinomas are defined as pituitary tumors greater than 4 cm, often associated with very high prolactin level (>1000 ng/mL). They are relatively rare tumors and can present differently from typical prolactinomas.
Kashif M Munir
exaly +4 more sources
SAGE Open Medical Case Reports, 2023 Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj +2 more sources
Aggressive giant prolactinoma: a case report
Journal of Medical Case Reports, 2022 Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan +1 more
doaj +3 more sources
Giant Prolactinoma Presenting With Neck Pain and Structural Compromise of the Occipital Condyles
Journal of Neurological Surgery Reports, 2015 Prolactinomas are the most common form of endocrinologically active pituitary adenoma; they account for ∼ 45% of pituitary adenomas encountered in clinical practice. Giant adenomas are those > 4 cm in diameter.
Laurence Katznelson +2 more
exaly +3 more sources
Frontiers in Endocrinology, 2019 Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C B Dantas +2 more
exaly +3 more sources
A Novel Germline CDH23 Variant as a Likely Cause of an Ultra-Giant Prolactinoma
Orphanet Journal of Rare DiseasesGiant prolactinomas are defined as pituitary adenomas (PAs) ≥ 4 cm with plasma prolactin level > 1000 ng/ml with no other co-secretory component. The reasons for development of giant prolactinomas are not clear but genetics play an important pathogenic ...
Eyas Othman +2 more
exaly +2 more sources
BMC Endocrine Disorders, 2023 Background Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive macroprolactinoma has the potential to cause base of skull erosion and extend into the nasal cavity or even the sphenoid sinus.
Danting Li +4 more
doaj +1 more source
Turkish Journal of Internal Medicine, 2022 Objective: Data on whether there is a histopathological difference in cellular features as determined with Ki-67 between giant prolactinomas and smaller macroprolactinomas are not fully clear.
Soner Cander, Özen Öz Gül
doaj +1 more source